143 related articles for article (PubMed ID: 24704438)
1. Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects.
Shete HK; Selkar N; Vanage GR; Patravale VB
Int J Pharm; 2014 Jul; 468(1-2):1-14. PubMed ID: 24704438
[TBL] [Abstract][Full Text] [Related]
2. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies.
Shete H; Chatterjee S; De A; Patravale V
Int J Pharm; 2013 Sep; 454(1):584-92. PubMed ID: 23535344
[TBL] [Abstract][Full Text] [Related]
3. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
Shete H; Patravale V
Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
[TBL] [Abstract][Full Text] [Related]
4. Alpha-lipoic acid-stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study.
Dhaundiyal A; Jena SK; Samal SK; Sonvane B; Chand M; Sangamwar AT
J Pharm Pharmacol; 2016 Dec; 68(12):1535-1550. PubMed ID: 27709612
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity.
How CW; Rasedee A; Manickam S; Rosli R
Colloids Surf B Biointerfaces; 2013 Dec; 112():393-9. PubMed ID: 24036474
[TBL] [Abstract][Full Text] [Related]
6. Formulation Development of Tamoxifen Loaded Lipid Nanoparticle by Taguchi (L
Poovi G; Damodharan N
Curr Comput Aided Drug Des; 2021; 17(1):144-159. PubMed ID: 32196454
[TBL] [Abstract][Full Text] [Related]
7. Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers.
Beh CY; How CW; Foo JB; Foong JN; Selvarajah GT; Rasedee A
Drug Des Devel Ther; 2017; 11():771-782. PubMed ID: 28352153
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
Li F; Weng Y; Wang L; He H; Yang J; Tang X
Int J Pharm; 2010 Jun; 393(1-2):203-11. PubMed ID: 20385221
[TBL] [Abstract][Full Text] [Related]
9. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer.
Guney Eskiler G; Cecener G; Dikmen G; Egeli U; Tunca B
Eur J Pharm Sci; 2018 Jul; 120():73-88. PubMed ID: 29719240
[TBL] [Abstract][Full Text] [Related]
10. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity.
Jain AK; Thanki K; Jain S
Mol Pharm; 2013 Sep; 10(9):3459-74. PubMed ID: 23927416
[TBL] [Abstract][Full Text] [Related]
11. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
12. Effective cellular internalization, cell cycle arrest and improved pharmacokinetics of Tamoxifen by cholesterol based lipopolymeric nanoparticles.
Mazumdar S; Italiya KS; Sharma S; Chitkara D; Mittal A
Int J Pharm; 2018 May; 543(1-2):96-106. PubMed ID: 29578081
[TBL] [Abstract][Full Text] [Related]
13. Potential of amphiphilic graft copolymer α-tocopherol succinate-g-carboxymethyl chitosan in modulating the permeability and anticancer efficacy of tamoxifen.
Jena SK; Samal SK; Kaur S; Chand M; Sangamwar AT
Eur J Pharm Sci; 2017 Apr; 101():149-159. PubMed ID: 28214545
[TBL] [Abstract][Full Text] [Related]
14. Improved Oral Bioavailability, Therapeutic Efficacy, and Reduced Toxicity of Tamoxifen-Loaded Liquid Crystalline Nanoparticles.
Jain S; Heeralal B; Swami R; Swarnakar NK; Kushwah V
AAPS PharmSciTech; 2018 Jan; 19(1):460-469. PubMed ID: 28785860
[TBL] [Abstract][Full Text] [Related]
15. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen.
Jain AK; Swarnakar NK; Godugu C; Singh RP; Jain S
Biomaterials; 2011 Jan; 32(2):503-15. PubMed ID: 20934747
[TBL] [Abstract][Full Text] [Related]
16. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate.
Hashem FM; Nasr M; Khairy A
Pharm Dev Technol; 2014 Nov; 19(7):824-32. PubMed ID: 24032414
[TBL] [Abstract][Full Text] [Related]
18. Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability.
Kapse SV; Gaikwad RV; Samad A; Devarajan PV
Int J Pharm; 2012 Jun; 429(1-2):104-12. PubMed ID: 22414426
[TBL] [Abstract][Full Text] [Related]
19. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy.
Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z
Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775
[TBL] [Abstract][Full Text] [Related]
20. Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics.
Misra C; Kumar M; Sharma G; Kumar R; Singh B; Katare OP; Raza K
Nanomedicine (Lond); 2017 May; 12(9):1011-1023. PubMed ID: 28440713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
